WNT5B exerts oncogenic effects and is negatively regulated by miR-5587-3p in lung adenocarcinoma progression

Qun, Zhang; Fan, He; Liu, Hongda; Jin, Jiajia; Zhu, Suhua; Zhou, Li; Liu, Hongbin; Zhang, Fang; Zhan, Ping; Lv, Tangfeng; Song, Yong

doi:10.1038/s41388-019-1071-4

Cited by 27 publications

(16 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many WNT ligands, both canonical and non-canonical, and WNT signaling proteins are misregulated in lung cancer. Specifically, both WNT5A and WNT5B are overexpressed in non-small cell lung cancers (NSCLC) compared to normal tissue and their overexpression is correlated with poor overall survival ( Huang et al, 2005 ; Zhang et al, 2020 ). Knockdown of WNT5B reduced the proliferation and growth rate of lung adenocarcinoma both in vitro and in vivo by inducing cell-cycle arrest at the G1/S phase.…”

Section: Role Of Wnt5b In Cancermentioning

confidence: 99%

WNT5B in Physiology and Disease

Suthon

Perkins

Bryja

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

WNT5B, a member of the WNT family of proteins that is closely related to WNT5A, is required for cell migration, cell proliferation, or cell differentiation in many cell types. WNT5B signals through the non-canonical β-catenin-independent signaling pathway and often functions as an antagonist of canonical WNT signaling. Although WNT5B has a high amino acid identity with WNT5A and is often assumed to have similar activities, WNT5B often exhibits unique expression patterns and functions. Here, we describe the distinct effects and mechanisms of WNT5B on development, bone, adipose tissue, cardiac tissue, the nervous system, the mammary gland, the lung and hematopoietic cells, compared to WNT5A. We also highlight aberrances in non-canonical WNT5B signaling contributing to diseases such as osteoarthritis, osteoporosis, obesity, type 2 diabetes mellitus, neuropathology, and chronic diseases associated with aging, as well as various cancers.

show abstract

Section: Role Of Wnt5b In Cancermentioning

confidence: 99%

WNT5B in Physiology and Disease

Suthon

Perkins

Bryja

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…MKN45 cells were transfected with shRNA plasmids using shRNA Plasmid Transfection Reagent (sc-108,061, Santa Cruz). 19 Transfected cells were selected by using puromycin. Specific siRNAs targeting MDM2 (sc-29,394) and SPRR2B (sc-88,442) were used for transient transfection, using non-specific scramble siRNA (sc-37,007) as negative control.…”

Section: Cell Culture and Transfectionmentioning

confidence: 99%

Small Proline-Rich Protein 2B Facilitates Gastric Adenocarcinoma Proliferation via MDM2-p53/p21 Signaling Pathway

Yao¹,

Yan²,

Cheng³

et al. 2021

OTT

View full text Add to dashboard Cite

Background The small proline-rich protein 2B (SPRR2B) was firstly reported as a member of the cross-linked envelope protein in keratinocytes. The effect of SPRR2B in gastric adenocarcinoma (GC) remains unclear. This study initially explored the clinical significance of SPRR2B in GC patients as well as its role in tumor progression. Methods Immunohistochemistry was performed to characterize the expression of SPRR2B in GC tissues and adjacent tissues. The relationship between SPRR2B expression and clinicopathological features of GC patients was analyzed by Chi-square test. Kaplan-Meier method and Cox regression analyses were utilized to identify the prognostic factors of GC. Overexpression and knockdown assays were conducted to investigate possible signaling pathways downstream of SPRR2B. Flow cytometry assays were performed to evaluate cell cycle and apoptosis. Xenograft experiments were performed to validate tumor-related role of SPRR2B in vivo. Results Both mRNA and protein levels of SPRR2B in cancerous tissue were significantly higher than those in non-cancerous tissues. Meanwhile, SPRR2B expression was significantly associated with tumor size and tumor stage. Survival analysis revealed SPRR2B as one of the independent prognosis factors for overall survival of GC patients. Cellular and xenografts data implicated that silencing SPRR2B blocked the cell cycle of GC cells perhaps through MDM2-p53/p21-CDK1 pathway, while overexpressing SPRR2B exhibited opposite effects. Conclusion Our data suggest that SPRR2B may serve as a novel prognostic marker in GC, which functions at least partially by MDM2-p53/p21-CDK1 signaling pathway.

show abstract

“…Mice were randomly assigned to the experimental group and the control group, and 5×10 6 stable-transfected cells were subcutaneously implanted into mice. 21 Tumor volumes were measured every 5 days to obtain the growth curve. After 20 days, all mice were sacrificed, and all xenografts were isolated and weighed.…”

Section: Xenograft Model Of Glioma In Nude Micementioning

confidence: 99%

<p>Bone Marrow Stromal Antigen 2 is a Potential Unfavorable Prognostic Factor for High-Grade Glioma</p>

Luo¹,

Huang²

2020

OTT

View full text Add to dashboard Cite

Background: Bone marrow stromal antigen 2 (BST2) is considered as a transmembrane glycoprotein and plays essential roles in innate immunity. It has been recently reported that up-regulation of BST2 was associated with the development of breast carcinoma. However, the clinical significance of BST2 in glioma has not been identified. The purpose of the present study is to explore the expression pattern and the role of BST2 in the progression of high-grade glioma. Methods: Expression levels of BST2 were tested in glioma tissues by analyzing the GEO database and immunohistochemistry staining. The prognostic role of BST2 in glioma was evaluated through univariate and multivariate analyses. In vitro and in vivo assays were conducted to confirm the role of BST2 on promoting glioma proliferation. Results: The mRNA level of BST2 was higher in glioma tissues than that in nontumorous brain tissues. High protein level of BST2 was correlated with larger tumor size and advanced WHO grade. Glioma patients with a high BST2 level had worse overall survival. In addition, BST2 was defined as an independent risk factor for glioma prognosis. Cellular and xenograft studies revealed that BST2 can significantly promote glioma proliferation. Conclusion: Our study revealed that a high BST2 expression level was closely related to the unfavorable clinical features and poor prognosis of high-grade glioma patients. BST2 may serve as an invaluable prognostic indicator and novel therapeutic target for glioma treatment considering its membrane localization.

show abstract

WNT5B exerts oncogenic effects and is negatively regulated by miR-5587-3p in lung adenocarcinoma progression

Cited by 27 publications

References 38 publications

WNT5B in Physiology and Disease

WNT5B in Physiology and Disease

Small Proline-Rich Protein 2B Facilitates Gastric Adenocarcinoma Proliferation via MDM2-p53/p21 Signaling Pathway

<p>Bone Marrow Stromal Antigen 2 is a Potential Unfavorable Prognostic Factor for High-Grade Glioma</p>

Contact Info

Product

Resources

About